Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
721-740 of 2,120 trials

Mpox Vaccination Study: MPOX-VAX

We are studying a vaccine to see how well it prevents Mpox infection and how long the immune response lasts. Participants will also be monitored for other infections to understand overall health impacts.

Mpox Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Advanced Cancer: Targeted Drug Study

We are investigating whether approved cancer drugs can help patients with advanced cancer who have specific genetic markers. This study aims to improve treatment options by using these drugs in new ways.

CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Isatuximab for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

We are studying whether Isatuximab can safely help adults with relapsed or refractory T-cell acute lymphoblastic leukemia achieve remission. This trial looks at its effects alone and with other chemotherapy drugs.

T-cell Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer: Raludotatug Deruxtecan Study

We are studying a new drug for patients with platinum-resistant, high-grade ovarian cancer. The goal is to see if it works better than current treatment options.

Ovarian and Related Cancers>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: First-in-Human Study of DS-3939a

We are testing a new treatment called DS-3939a to see if it is safe and effective for people with advanced solid tumors. This study aims to understand how well it works and its effects on tumor tissue.

Metastatic Solid TumorAdvanced Solid TumorSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Biliary Tract Cancers: [18F]F-FAPI PET-CT Imaging Study

We are investigating how a new imaging technique may improve diagnosis and treatment planning for patients with potentially resectable biliary tract cancers. This study will also look at the cost-effectiveness and safety of this imaging method.

Cholangiocarcinoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Colchicine for Angina in Microvascular Disease

We are studying whether colchicine can improve blood flow and reduce symptoms in patients with angina caused by coronary microvascular dysfunction. This research may help us understand how to better treat this condition.

Cardiovascular Disease (CMD)>2 yearsEfficacy phase (II)Standard MedicinesCardiology

Pompe Disease: Enzyme Replacement Therapy Study

We are examining how a new enzyme replacement therapy affects muscle glycogen in people with Pompe disease who have not yet received treatment. This research may help improve future therapies for this condition.

Pompe's Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyHematologyNeurology

Ovarian Cancer: Sacituzumab Tirumotecan Study

We are testing a new treatment for people with recurrent ovarian cancer to see if it works better than standard care. This study looks at safety, tolerability, and how it affects patients' quality of life.

Recurrent Ovarian CancerConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Levosimendan for Heart Support During ECMO Weaning

We are studying whether Levosimendan can improve heart function in patients being weaned from ECMO. This may help reduce complications and support recovery during this critical period.

Cardiogenic ShockEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Eosinophilic Granulomatosis with Polyangiitis: Mepolizumab Treatment

We are studying how mepolizumab affects the nasal microbiome and immune response in patients with eGPA. This research may help understand its impact on local inflammation in the ENT area.

Eosinophilic Granulomatosis with Polyangiitis (eGPA)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Acute Myeloid Leukemia: Vyxeos and Clofarabine Study

We are testing a new combination treatment for children with relapsed or refractory AML to find the best dose and evaluate its safety. The study aims to see if this treatment can help achieve remission and support future stem cell transplants.

Acute Myeloid LeukemiaSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Endometrial Cancer: New Treatment Combinations

We are studying whether a new combination of Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab is more effective than standard chemotherapy for patients with advanced or recurrent HER2-expressing endometrial cancer.

Endometrial CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Dupilumab for Chronic Rhinosinusitis with Nasal Polyps

We are studying how dupilumab affects ear symptoms and hearing in patients with chronic rhinosinusitis and eosinophilic otitis media. This research aims to improve understanding of treatment benefits for these conditions.

Chronic Rhinosinusitis with Nasal PolypsEosinophilic Otitis Media>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

CRSwNP: Predicting Response to Mepolizumab

We are studying biomarkers to see if they can help predict how well patients with CRSwNP respond to the treatment mepolizumab. This research aims to improve personalized treatment options for these patients.

Chronic Rhinosinusitis with Nasal Polyps≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

Advanced Colon Cancer: Preoperative Chemotherapy Study

We are investigating whether chemotherapy before surgery is more effective than surgery followed by additional treatment for advanced colon cancer. This trial aims to improve treatment strategies for patients.

Colon Cancer (Stage T3-4)>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology